Erasca, Inc. (ERAS): Operating Cash Flow
-$95.45M
Year ended 2025-12-31
-$98.02M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$95.45M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$109.42M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$101.22M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$103.26M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$79.60M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$32.69M | n/a | 2022-03-24, From 2020-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | -$95.45M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $127.04M | +22.7% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$138.89M | n/m |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | -$1.38M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $43.86M | n/m |
| Nkarta, Inc. (NKTX) | 2025-12-31 | -$88.70M | n/m |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | -$79.95M | n/m |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | -$110.97M | n/m |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | -$172.33M | n/m |
Compare ERAS, IRWD, TNGX, OTLC side by side · Screen every company in Pharmaceutical Preparations ↗